Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Cancer
NCT07096362Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Sep 2025
- Primary completion
- Sep 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, oxaliplatin, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, gemcitabine in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Miami. Started Sep 2025; status: recruiting.
02
Drugs
fluorouraciloxaliplatinfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabgemcitabine
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07096362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096362.